TACE Drug Patent Profile

Which patents cover Tace, and what generic alternatives are available?

Tace is a drug marketed by Sanofi Aventis Us and is included in three NDAs.

The generic ingredient in TACE is chlorotrianisene. Additional details are available on the chlorotrianisene profile page.

Summary for TACE

US Patents:	0
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for TACE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TACE	chlorotrianisene	CAPSULE;ORAL	008102-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	TACE	chlorotrianisene	CAPSULE;ORAL	011444-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	TACE	chlorotrianisene	CAPSULE;ORAL	016235-001	Approved Prior to Jan 1, 1982		DISCN	No	No

TACE (Thrombolysis with Alteplase) Drug-Development and Investment Fundamentals

Last updated: April 25, 2026

What is TACE and what indications matter for funding risk and upside?

“TACE” is used in two different ways across pharmaceutical and healthcare markets. The investment and IP picture changes materially depending on which meaning the market is pricing.

1) TACE as a therapy (Transarterial Chemoembolization)

• A locoregional procedure used in liver cancers, especially hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA).
• It is typically billed and governed as a procedure plus drug use (chemo agents delivered intra-arterially) rather than a single approved “drug” product.

2) TACE as a drug acronym (Thrombolysis with Alteplase)

• Alteplase is the active drug; “TACE” is not the global standard regulatory label for alteplase in oncology markets.
• Alteplase has separate thrombolysis indication sets (stroke, pulmonary embolism, etc.), with very different IP status and payer structure.

Investment implication: “TACE” as a single investable asset only exists where the market prices it as an approved drug or a proprietary product. Where it is a procedure, the investment case is often tied to interventional devices, embolic platforms, catheter systems, oncology drug logistics, and evidence generation rather than classic small-molecule/biologic IP.

Given the ambiguity, the only defensible investment-fundamentals analysis requires mapping “TACE” to a specific regulated therapy category. Without that mapping, any fundamentals model would mix oncology procedure economics with thrombolysis drug economics and misstate IP, cash-flow drivers, and competitive risk.

Is the market pricing a drug product or a procedure platform?

Regulatory and reimbursement “unit of value”

Market framing	What payers reimburse	What investors underwrite	Core risk
Procedure (TACE for HCC)	Procedure + associated supplies/drugs	Procedure throughput, hospital adoption, evidence, site-of-care economics	Practice standard shifts, comparative effectiveness, guideline position
Drug (altepase-based acronym use)	Drug supply (alteplase) per treated patient	Patent/market exclusivity for drug entity and indication expansion	Patent expiry, biosimilar/alternative thrombolytics, guideline inclusion

For investment analysis, the unit of value must be consistent. Procedure-based “TACE” is an adoption and outcomes play. Drug-based “TACE” is an IP and payer-volume play.

What is the competitive landscape that drives pricing power?

Procedure-based TACE (HCC/iCCA): competition is method and chemoembolization strategy

Competitive differentiation typically comes from:

• Embolic delivery systems (particles, drug-eluting beads, delivery catheter compatibility)
• Chemo agent selection and dosing strategy
• Combination regimens (sequencing with immunotherapy or systemic therapy)
• Imaging and catheterization logistics (workflow and complication rates)

Drug-based “TACE” (altepase-based): competition is thrombolytic class and alternatives

Competitive differentiation comes from:

• Clinical guideline positioning vs tenecteplase, reteplase, other thrombolytics, and protocol alternatives
• Access and formulary status by geography and indication
• Safety profile and administration workflows

For a fundamentals model, the competitive set is different. Procedure economics depend on procedural volume and evidence for survival/response endpoints; drug economics depend on drug patent status and payor formulas.

What are the core fundamentals investors analyze?

If TACE is a procedure (HCC/iCCA), fundamentals are adoption and clinical positioning

Key fundamentals typically include:

• Guideline inclusion (recommended for specific stages and performance status)
• Outcomes evidence (overall survival, time-to-progression, objective response)
• Hospital capacity and throughput (interventional radiology scheduling)
• Complication rates and re-admission costs
• Ability to scale with systemic therapy combinations without undermining efficacy endpoints

If TACE is a drug (alteplase-based), fundamentals are IP durability and indication volume

Key fundamentals typically include:

• Patent life and exclusivity by jurisdiction
• Biosimilar/small-molecule generic pressure (for alteplase, biosimilar competition is the defining variable)
• Indication expansion (new approved populations)
• Hospital formulary dynamics (procurement and switching)
• Reimbursement level and utilization management

What does an “investment scenario” look like for procedure-based TACE?

Base-case scenario drivers

• Stable or growing number of diagnosed HCC/iCCA patients in relevant geographies
• Continued role of TACE in intermediate-stage management or selected conversion/downstaging pathways
• Increased share of centers using optimized chemoembolization platforms

Upside scenarios

• Better survival or response evidence supports broader use or earlier line positioning
• Stronger performance in combination with systemic regimens that become standard of care
• Lower complication burden via device/platform improvements, improving payer confidence

Downside scenarios

• Shifts toward systemic-first paradigms reduce TACE utilization in earlier disease stages
• Comparative effectiveness fails in pivotal endpoints vs alternatives
• Capacity constraints or increased adverse events degrade adoption

What does an “investment scenario” look like for drug-based TACE (alteplase)?

Base-case scenario drivers

• Stable acute thrombolysis volumes in established indications
• Maintenance of formulary status versus competitors
• Ongoing guideline adherence to alteplase where it remains best-in-class

Upside scenarios

• Indication expansion or line-of-therapy changes favor alteplase
• Superior safety or workflow economics vs alternative thrombolytics

Downside scenarios

• Increased biosimilar/generic pressure reducing net pricing
• Guideline drift toward alternative agents with better outcomes or easier administration

What are the financial and operational KPIs to underwrite?

For procedure-based TACE

• Procedure volume growth by site and region
• Case mix (intermediate-stage vs downstaging/high-risk cohorts)
• Average selling price for platform components (if investor-backed product is embedded in procedure)
• Reimbursement stability and billing codes by geography
• Rate of complications that drive length of stay and payer penalties
• Evidence milestones that affect guideline position

For drug-based alteplase (if that is what “TACE” refers to)

• Net sales per treated patient (post-discount) and growth vs biosimilar penetration
• Share of treated population in each indication by geography
• Formulary status and switching patterns
• Gross-to-net bridge (rebates, contracts, tendering)
• R&D pipeline focused on next-gen thrombolytics or improved formulations (if any)

What IP and pipeline factors matter most?

Procedure-based TACE

The strongest IP is often:

• Device/platform and delivery method IP
• Formulation IP for drug-eluting embolic beads
• Combination regimen evidence generated through trials (less “patentable,” but commercially critical)

Drug-based alteplase

The strongest fundamentals factor is:

• Patent and exclusivity timeline versus biosimilar approvals
• The ability to retain share via clinical and formulary position even as prices compress

Without a defined asset mapping (procedure platform vs drug product), IP assessment cannot be correctly applied.

What diligence questions should drive an investment decision?

This is the diligence map that prevents category errors when “TACE” is used as an umbrella label.

Category confirmation

• Determine if the investable asset is a procedure platform, device, or drug product tied to regulated drug labels.

Evidence alignment

• Identify the exact clinical endpoints and line-of-therapy positioning the market is crediting.
• Confirm whether endpoints support guideline adoption in the specific disease stage.

Reimbursement and site dynamics

• Validate payer coverage by stage and regimen combinations.
• Confirm hospital adoption drivers: workflow, complication management, and availability.

Competition and switching

• Map substitutes: other embolization methods, radiation alternatives, systemic-first strategies, or thrombolytic alternatives depending on category.

Key Takeaways

• “TACE” is not a single universally defined drug asset. It is used both as a procedure (transarterial chemoembolization for liver cancer) and as an acronym sometimes tied to thrombolysis (alteplase). These are different investment categories with different fundamentals.
• Procedure-based TACE upside is driven by guideline position, procedural throughput, outcomes, and platform adoption. Downside comes from systemic-first shifts or weaker comparative effectiveness.
• Drug-based alteplase upside is driven by formulary retention, indication volume, and any exclusivity durability. Downside comes from biosimilar and competitor substitution and guideline drift.

FAQs

1) Is TACE an approved drug?
TACE is most commonly used to describe a procedure in liver oncology (transarterial chemoembolization), not a single drug product.

2) What determines revenue growth for procedure-based TACE?
Hospital adoption, procedure volume, case mix, and reimbursement stability for the overall treatment pathway.

3) What determines revenue growth for alteplase-like TACE usage?
Net pricing after contracting, formulary position, indication volumes, and competitive substitution from other thrombolytics and biosimilars.

4) What is the biggest downside risk for TACE (HCC context)?
Guideline and practice shifts toward alternatives that reduce the role of TACE in earlier lines or broader populations.

5) What is the biggest downside risk for alteplase-based TACE?
Price compression and share loss from biosimilar and competitor thrombolytics, plus protocol and guideline changes.

---

References

[1] National Cancer Institute. “Transarterial Chemoembolization (TACE).” PDQ Cancer Information Summaries.
[2] FDA. Product labeling and approval information for alteplase (Activase) and indication-specific details.
[3] ESMO Clinical Practice Guidelines. Hepatocellular carcinoma treatment recommendations (TACE role and stage positioning).
[4] NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary cancers (HCC/iCCA) treatment pathway references for locoregional therapy role.